B · Normal
[Tonghua Jinma: Category 1 innovative drug Avicridine Succinate Tablets is included in the national medical insurance catalog For the treatment of symptoms of mild and moderate Alzheimer's disease] On November 15th, Tonghua Jinma (000766.SZ) announced that the company's independently developed chemical Class 1 innovative drug Aviacridine Succinate Tablets has been included in the "National Medical Insurance Catalog" (2026 edition) for the first time, and is used for the treatment of symptoms of mild and moderate Alzheimer's disease. The agreement is valid from January 1, 2027 to December 31, 2028. The inclusion of the drug in medical insurance will help reduce patients' medication burden, improve drug accessibility, have a positive effect on product marketing and sales volume, and is conducive to the company's long-term business development.
A-share announcement express 🕐 2026-11-15 16:12

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet